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Background: Zoledronic acid has been shown to signiﬁcantly reduce 
the risk of skeletal-related events (SREs) such as pathologic fractures in 
patients with bone metastases from solid tumors. Exploratory analyses 
have suggested that fractures correlate with reduced survival in patients 
with malignant bone disease. Moreover, increased risks for skeletal 
morbidity and death have been reported in patients with bone metasta-
ses and high levels of N-telopeptide of type I collagen (NTX) com-
pared with patients with low NTX levels. Zoledronic acid was found 
to normalize NTX levels in approximately 80% of patients with bone 
metastases and elevated baseline NTX. To assess the potential effect 
on survival of zoledronic acid-induced normalization of high baseline 
NTX, we conducted a retrospective analysis of patients with bone 
metastases from non-small cell lung cancer (NSCLC) or other solid 
tumors (OST) in a large, randomized, controlled trial (Rosen LS, et al. 
Cancer. 2004;100:2613-2621).
Methods: In this pivotal phase III study, patients with NSCLC or OST 
(N = 773) were randomized to receive either zoledronic acid or placebo 
for up to 21 months. Patients were assessed for SREs and survival. 
Patients in the subset with baseline and 3-month NTX information 
available were retrospectively categorized at these timepoints as having 
normal NTX/creatinine (<64 nmol/mmol) or elevated NTX/creati-
nine (≥64 nmol/mmol). Relative risk of death was calculated for each 
patient group.
Results: Patient demographics and baseline disease characteristics 
were well balanced between treatment groups. Zoledronic acid-treated 
patients with NSCLC or OST included in this analysis (n = 204; 65% 
men, 35% women) had a mean age of 62 years. In this subgroup, 
overall mean NTX/creatinine ratio decreased from 88.2 to 35.8 nmol/
mmol after 3 months of zoledronic acid treatment; results were similar 
considering only patients with NSCLC. Among the ~40% of patients 
who had elevated baseline NTX levels, NTX normalization at 3 months 
was associated with a signiﬁcant 57% decrease in risk of death in the 
overall trial population (n = 87; P = .012) and improved survival in the 
NSCLC subset (46% risk reduction; n = 49; P = .142) compared with 
patients whose NTX levels remained elevated. Normalization of NTX 
at 3 months was also associated with a signiﬁcant 61% decrease in risk 
of bone disease progression in the overall trial population (P = .023) 
and improved bone progression-free survival in the NSCLC population 
(52% risk reduction; P = .174) compared with patients whose NTX 
levels remained elevated.
Conclusions: Although this trial was not statistically powered to 
detect patterns in survival or bone lesion progression, especially in 
the NSCLC subset, there were consistent correlations between NTX 
normalization and delayed time to death and bone lesion progression. 
Absolute changes in bone marker levels are not validated surrogates 
for clinical efﬁcacy. However, these analyses suggest that patients 
with bone metastases from solid tumors whose baseline NTX normal-
ized within 3 months of zoledronic acid treatment may have a survival 
advantage, and results for the NSCLC subset are consistent with this 
ﬁnding.
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Background: Somatic mutations in the epidermal growth factor recep-
tor (EGFR) gene have been considered as the most sensitive response 
predictor to the treatment of EGFR tyrosine kinase inhibitors (EGFR-
TKIs) in non-small cell lung cancers (NSCLC). Malignant pleural 
effusion is a frequent complication in advanced NSCLC patients (up 
to 50%) which often necessitate thoracentasis or chest tube drainage. 
Several studies have reported detection of EGFR mutation in ma-
lignant cells of pleural effusion. In this study we determined EGFR 
mutation status with use of both cells isolated from pleural effusions 
and cell-free pleural ﬂuid with the primary objective to compare the 
concordance of mutation spectrum obtained from the paired specimens 
and to deﬁne the clinical signiﬁcance of pleural effusion in mutation 
screening. We also intended to study the sensitivity of different detec-
tion methods.
Methods: Pleural effusion specimens were obtained from 26 East 
Asian patients with advanced NSCLC. Genomic DNA from both 
pleural effusion cells and cell-free pleural ﬂuid were extracted. EGFR 
mutations in exons 18-21 were screened using automatic sequencing. 
Mutations in exon 19 were further analyzed with mutant-enriched PCR 
and gene scan analysis.
Result: A total of 5 mutations from pleural effusion cells (2 deletion 
mutations in exon 19, 1 missense mutation in exon 20, and 2 L858R 
in exon 21) were detected by sequencing. Interestingly, 2 additional 
deletion mutations in exon 19 were found from cell-free pleural ﬂuid. 
Mutant-enriched PCR and gene scan analysis not only conﬁrmed all the 
detected deletion mutations but also identiﬁed another 5 deletion muta-
tions from both specimens. No mutations were detected in exon 18. 
Conclusion: EGFR mutations can be detected in both malignant cells 
and cell free pleural effusions. Cell-free pleural ﬂuid could provide 
more mutation information than pleural effusion cells when sequencing 
analysis is applied. Our observation implies that DNA compositions 
of the two types of specimens are different and more free DNA from 
malignant cells could be present in the ﬂuid. Mutant-enriched PCR plus 
gene scan analysis is much more sensitive for mutation detection com-
pared to direct sequencing. Malignant pleural effusion is a convenient 
and more readily available specimen than primary tumor for detecting 
EGFR mutation in NSCLC.
